Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

This article details the proposals of the IWGM-MDS for the definition of myeloblasts, promyelocytes and ring side-roblasts in patients with myelodysplastic syndrome. The classification of myelodysplastic syndromes is based on the morphological criteria proposed by the French-American-British (FAB) and World Health Organization (WHO) groups. Accurate enumeration of blast cells, although essential for diagnosis of myelodysplastic syndrome and for assignment to prognostic groups, is often difficult, due to imprecise criteria for the morphological definition of blasts and promyelocytes. An International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) of hematopathologists and hematologists expert in the field of myelodysplastic syndrome reviewed the morphological features of bone marrows from all subtypes of myelodysplastic syndrome and agreed on a set of recommendations, including recommendations for the definition and enumeration of blast cells and ring sideroblasts. It is recommended that (1) agranular or granular blast cells be defined (replacing the previous type I, II and III blasts), (2) dysplastic promyelocytes be distinguished from cytologically normal promyelocytes and from granular blast cells, (3) sufficient cells be counted to give a precise blast percentage, particularly at thresholds that are important for diagnosis or prognosis and (4) ring sideroblasts be defined as erythroblasts in which there are a minimum of 5 siderotic granules covering at least a third of the nuclear circumference. Clear definitions and a differential count of a sufficient number of cells is likely to improve precision in the diagnosis and classification of myelodysplastic syndrome. Recommendations should be applied in the context of the WHO classification.

[1]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[2]  K. Mitani [Myelodysplastic syndrome]. , 2020, Nihon rinsho. Japanese journal of clinical medicine.

[3]  M. Cazzola,et al.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Bain,et al.  C005 New definitions for blast cells in AML and MDS with validation by virtual microscopy , 2007 .

[5]  J. Bennett,et al.  Evolving classifications of the myelodysplastic syndromes , 2007, Current opinion in hematology.

[6]  G. Mufti Pathobiology, classification, and diagnosis of myelodysplastic syndrome. , 2004, Best practice & research. Clinical haematology.

[7]  G. Mufti,et al.  Targeted therapies in myeloid leukemia. , 2004, Seminars in cancer biology.

[8]  D. Hossfeld E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[9]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[10]  H. A. Varol,et al.  Erratum: Human grasping database for activities of daily living with depth, color and kinematic data streams , 2018, Scientific Data.

[11]  J. Bennett,et al.  Prognostic implication and characterization of the blast cell population in the myelodysplastic syndrome. , 1991, Leukemia research.

[12]  F. Sigaux,et al.  Haematological features of primary myelodysplastic syndromes (PMDS) at initial presentation: a study of 118 cases. , 1983, Journal of clinical pathology.

[13]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.